Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer

Table 4 Cause of death in patients who died within 14 days or during 15–30 days of systemic anti-cancer treatment

Characteristics	≤ 14 days N = 33	15–30 days N = 39	Total N = 72	p
Died after 1st SACT cycle, N (%)	16 (48.5)	9 (23.1)	25 (34.7)	0.03
Total SACT cycles (median, range)	2 (1–13)	4 (1–17)	3 (1–17)	0.06
NEU before last cycle, N (%)	5 (15.2)	1 (2.6)	6 (8.3)	0.09
GCS-GF^a	3 (9)	3 (7.7)	6 (8.3)	1
NEU/PAN after last cycle	9 (27.3)	5 (12.8)	14 (19.4)	0.145
ICU before death	15 (45.5)	5 (12.8)	20 (27.8)	0.003
Cause of death, N (%)				0.09
CV	3 (9.1)	3 (7.7)	6 (8.3)
INF	9 (27.3)	7 (18)	16 (22.2)
PD	13 (39.4)	26 (66.7)	39 (54.2)
SUDDEN	8 (24.2)	3 (7.7)	11 (15.3)

Abbreviations: SACT Systemic anti-cancer treatment, NEU Neutropenia, INF Infection, PD Progression, GCS-GF Granulocyte colony stimulating growth factor, PAN Pancytopenia, ICU Intensive care unit admission, CV Cardiovascular, SUDDEN sudden death or unknown with good performance status at the time of last SACT
^aGCS-GF primary prophylaxis before last cycle. Values in bold are significant at p < 0.05

ISSN: 1471-2407